In this interview, Fabien De Coninck and Bruno Morchain discuss Aptar Pharma’s eco-design philosophy. In a thorough conversation, they cover how Aptar Pharma has implemented lifecycle assessments as a key tool to elucidate the environmental footprint of the company’s rubber components for primary packaging for injectable systems, including how they tackled the unique challenges presented by the complex, proprietary formulations involved in elastomer component design.
In their discussion with On Drug Delivery’s Guy Furness, Bruno Morchain and Fabien De Coninck from Aptar Pharma discuss the company’s structured approach to sustainability, focusing especially on injectable drug delivery systems.
Aptar Pharma integrates environmental, social, and economic considerations into its strategy, with a strong focus on employees, communities, and the environment. This commitment is highlighted by Aptar Pharma’s Futurity™ platform of solutions that support a circular approach in the packaging industry.
In injectable packaging, especially when talking about elastomeric components like Aptar Pharma’s vial stoppers and pre-filled syringe components, the proprietary composition of rubber materials and their classification as biohazardous waste present significant challenges that prevent their entry into standard recycling streams. To address these complexities and support the company’s sustainability commitments, the division has adopted initiatives to reduce the environmental footprint and achieve its sustainability objectives, such as landfill-free production processes and utilizing renewable energy throughout its facilities.
Read our article to learn more about Aptar Pharma Injectables’ initiatives supporting its commitment to sustainability and the significance of conducting comprehensive life cycle assessments of its products as an essential tool for developing a robust eco-design strategy.